Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation.
Sølund, Christina; Hallager, Sofie; Pedersen, Martin S; Fahnøe, Ulrik; Ernst, Anja; Krarup, Henrik B; Røge, Birgit T; Christensen, Peer B; Laursen, Alex L; Gerstoft, Jan; Bélard, Erika; Madsen, Lone G; Schønning, Kristian; Pedersen, Anders G; Bukh, Jens; Weis, Nina.
Scand J Gastroenterol
; 53(7): 849-856, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29720023
Pioneering a Global Cure for Chronic Hepatitis C Virus Infection.
The oncologic burden of hepatitis C virus infection: A clinical perspective.
Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience.
Hepatitis C reinfection after sustained virological response.
Urgency to treat patients with chronic hepatitis C in Asia.
Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective.
The changing burden of hepatitis C virus infection in the United States: model-based predictions.
[Real-world study of paritaprevir/ritonavir-ombitasvir combined with dasabuvir for the treatment of chronic hepatitis C 1b genotype infection in China].
Liver mortality attributable to chronic hepatitis C virus infection in Denmark and Scotland--using spontaneous resolvers as the benchmark comparator.
Prevalence of occult hepatitis C virus infection in patients who achieved sustained virologic response to direct-acting antiviral agents.